Navigation Links
Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
Date:9/24/2008

Opening Ceremony Launches Effort to Transform Korean Pharmaceutical Industry

CHUNCHEON CITY, Korea, Sept. 24 /PRNewswire-USNewswire/ --

Civic and business officials gathered in Chuncheon City Sept. 23 to open a worldwide bioequivalence research institute operated by International Scientific Standard, Inc. (ISS), a joint venture company.

ISS, formed by Battelle and YuYu Pharma, will focus on testing the safety and efficacy of generic drugs in order to position the Korean pharmaceutical market for global sales. The ISS pledges to work closely with customers to ensure testing meets global standards.

Bioequivalence testing services begin in the fall in the GLP-compliant laboratory, which will begin operation with 10 to 20 researchers. They'll conduct the work in a 1,090-square meter facility in Chuncheon City that is equipped with state-of-the-art LC/MS equipment imported from Japan and the United States.

The opening ceremony was attended by: Kim Jin Son, Kang Won Provincial Governor; Lee Kwang Jun, Chuncheon Mayor; Dr. Carl Kohrt, Battelle President and CEO; and Dr. Seungpil Yu, Chairman of YuYu Pharma.

Officers of ISS include YuYu Pharma's Dr. Seungpil Yu, who is Chairman of the Board, and Battelle's Dr. Joan Adams, who is Representative Director.

Chuncheon City offered incentives in order to bring the ISS facility to the city because it has the potential to have a positive impact on the economy. Chuncheon estimates new drug development production could eventually reach $168 million annually and potentially create 3,000 jobs.

YuYu Inc. is a pharmaceutical company listed on the Korea Stock Exchange.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. Battelle oversees $4 billion in research and 20,400 staff members in more than 120 locations around the world.

For more information contact Public Relations Manager Katy Delaney at

(410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... of America (UCAOA) and College of Urgent Care Medicine will host industry leaders ... sessions and speakers will help those in the industry adapt to the issues ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept ... a hearing aid doesn’t have the stigma it had when great-grandpa wore his hearing ... Greater Boston, in a NALA North American Speaker Series (NASS) segment. “He ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: